Use of A2A adenosine receptor agonists

US7655636B2 · kind B2 · utility

Assignee

• Gilead Palo Alto, Inc. · US

Inventors

• Toufigh Gordi · Sunnyvale, US
• Ann Walls Olmsted · Palo Alto, US
• Hsiao Lieu · Burlingame, US
• Luiz Belardinelli · Palo Alto, US

Key dates

• Filing date: Oct 19, 2005
• Grant date: Feb 2, 2010
• Expiry date: Oct 19, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/0019
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, — an adenosine A2A receptor agonist — to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.